Literature DB >> 30012761

Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis.

Ariane J Sousa-Batista1, Douglas Escrivani-Oliveira1, Camila Alves Bandeira Falcão1, Cintia Iana Monteiro da Silva Philipon1, Bartira Rossi-Bergmann2.   

Abstract

The oral efficacy and safety of a leishmanicidal nitrochalcone (CH8) were studied in BALB/c mouse infections with Leishmania amazonensis and Leishmania infantum Although 10-fold-higher doses of CH8 were needed to produce the same antiparasitic effect as that seen with the reference drug miltefosine, the latter was nephrotoxic, whereas CH8 restored disease toxicity markers to normal. This study shows the therapeutic potential of an orally active and hepato-/nephroprotective chalcone against cutaneous and visceral leishmaniases.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  chalcone; chemotherapy; leishmaniasis

Mesh：

Substances：

Year:  2018        PMID： 30012761      PMCID： PMC6153786          DOI： 10.1128/AAC.00792-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis.

Authors:  E C Torres-Santos; D L Moreira; M A Kaplan; M N Meirelles; B Rossi-Bergmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.

Authors:  Cynthia Demicheli; Rosemary Ochoa; José B B da Silva; Camila A B Falcão; Bartira Rossi-Bergmann; Alan L de Melo; Ruben D Sinisterra; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

3.  Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.

Authors:  Swati Jaiswal; Mahendra Shukla; Abhisheak Sharma; Nagarjun Rangaraj; Kalpesh Vaghasiya; Mohd Yaseen Malik; Jawahar Lal
Journal:  Drug Test Anal       Date:  2016-11-28       Impact factor: 3.345

4.  Lipid-core nanocapsules increase the oral efficacy of quercetin in cutaneous leishmaniasis.

Authors:  A J Sousa-Batista; F S Poletto; C I M S Philipon; S S Guterres; A R Pohlmann; B Rossi-Bergmann
Journal:  Parasitology       Date:  2017-06-27       Impact factor: 3.234

5.  Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca2+ Channel.

Authors:  Andrea K Pinto-Martinez; Jessica Rodriguez-Durán; Xenon Serrano-Martin; Vanessa Hernandez-Rodriguez; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 6.  Miltefosine: oral treatment of leishmaniasis.

Authors:  Jaime Soto; Paula Soto
Journal:  Expert Rev Anti Infect Ther       Date:  2006-04       Impact factor: 5.091

Review 7.  Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Authors:  Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter J de Vries
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790

8.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.

Authors:  Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida
Journal:  PLoS Negl Trop Dis       Date:  2016-01-27

Review 9.  Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.

Authors:  Fernanda Ventin; Carolina Cincurá; Paulo Roberto Lima Machado
Journal:  Expert Rev Anti Infect Ther       Date:  2018-02-16       Impact factor: 5.091

10.  In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.

Authors:  Adriano C Coelho; Cristiana T Trinconi; Carlos H N Costa; Silvia R B Uliana
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17
View more
  3 in total

1.  Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.

Authors:  Luciana M Ribeiro Antinarelli; Nícolas Glanzmann; Débora V C Mendonça; Daniela P Lage; João A Oliveira-da-Silva; Grasiele S V Tavares; Ana Maria R S Carvalho; Camila S Freitas; Vívian T Martins; Mariana C Duarte; Daniel Menezes-Souza; Adilson David da Silva; Eduardo Antônio Ferraz Coelho; Elaine Soares Coimbra
Journal:  Parasitol Res       Date:  2022-05-26       Impact factor: 2.383

2.  Chalcones identify cTXNPx as a potential antileishmanial drug target.

Authors:  Douglas O Escrivani; Rebecca L Charlton; Marjolly B Caruso; Gabriela A Burle-Caldas; Maria Paula G Borsodi; Russolina B Zingali; Natalia Arruda-Costa; Marcos V Palmeira-Mello; Jéssica B de Jesus; Alessandra M T Souza; Bárbara Abrahim-Vieira; Stefanie Freitag-Pohl; Ehmke Pohl; Paul W Denny; Bartira Rossi-Bergmann; Patrick G Steel
Journal:  PLoS Negl Trop Dis       Date:  2021-11-15

3.  Design, synthesis and biological evaluation of N-oxide derivatives with potent in vivo antileishmanial activity.

Authors:  Leandro da Costa Clementino; Guilherme Felipe Santos Fernandes; Igor Muccilo Prokopczyk; Wilquer Castro Laurindo; Danyelle Toyama; Bruno Pereira Motta; Amanda Martins Baviera; Flávio Henrique-Silva; Jean Leandro Dos Santos; Marcia A S Graminha
Journal:  PLoS One       Date:  2021-11-01       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.